BR112018067721A2 - anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares - Google Patents
anticorpos específicos para tau hiperfosforilada para o tratamento de doenças ocularesInfo
- Publication number
- BR112018067721A2 BR112018067721A2 BR112018067721A BR112018067721A BR112018067721A2 BR 112018067721 A2 BR112018067721 A2 BR 112018067721A2 BR 112018067721 A BR112018067721 A BR 112018067721A BR 112018067721 A BR112018067721 A BR 112018067721A BR 112018067721 A2 BR112018067721 A2 BR 112018067721A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- specific antibodies
- hyperphosphorylated tau
- eye diseases
- tau specific
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção baseia-se em anticorpos que são tanto altamente específicos para tau p-s396 hiperfosforilada patogênica como altamente específicos para as seções marcadas da retina humana, bem como a métodos de utilização destes anticorpos e seus fragmentos de ligação de tau no tratamento de amiloidose retinoide, degeneração macular relacionada com a idade (dmri) e glaucoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700006 | 2017-01-04 | ||
PCT/EP2018/050149 WO2018127519A1 (en) | 2017-01-04 | 2018-01-03 | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018067721A2 true BR112018067721A2 (pt) | 2019-01-08 |
Family
ID=62789197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018067721A BR112018067721A2 (pt) | 2017-01-04 | 2018-01-03 | anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares |
Country Status (7)
Country | Link |
---|---|
US (1) | US10995137B2 (pt) |
EP (1) | EP3565836A1 (pt) |
JP (1) | JP7217710B2 (pt) |
CN (1) | CN110267985B (pt) |
BR (1) | BR112018067721A2 (pt) |
MA (1) | MA47205A (pt) |
WO (1) | WO2018127519A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
LT3484916T (lt) | 2016-07-12 | 2021-04-26 | H. Lundbeck A/S | Antikūnai, būdingi hiperfosforilintam tau, ir jų naudojimo būdai |
WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
CN113631700A (zh) * | 2019-03-18 | 2021-11-09 | 瑞泽恩制药公司 | 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台 |
US11781131B2 (en) | 2019-03-18 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
CN111349617B (zh) * | 2020-05-25 | 2020-09-22 | 苏州仁端生物医药科技有限公司 | 一种分泌抗Tau或pTau-181/231/396单克隆抗体杂交瘤细胞株及其应用 |
WO2022140463A1 (en) * | 2020-12-22 | 2022-06-30 | Herzlinger Regina E | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
US11806507B2 (en) | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
ES2136654T3 (es) | 1991-12-06 | 1999-12-01 | Max Planck Gesellschaft | Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer. |
ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
ES2228467T3 (es) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US20070134724A1 (en) | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
MX338421B (es) | 2010-10-07 | 2016-04-15 | Ac Immune Sa | Anticuerpos fosfoespecificos que reconocen la proteina tau. |
RU2639537C2 (ru) | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
US10132818B2 (en) * | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
LT3484916T (lt) | 2016-07-12 | 2021-04-26 | H. Lundbeck A/S | Antikūnai, būdingi hiperfosforilintam tau, ir jų naudojimo būdai |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2018
- 2018-01-03 EP EP18702407.0A patent/EP3565836A1/en active Pending
- 2018-01-03 WO PCT/EP2018/050149 patent/WO2018127519A1/en unknown
- 2018-01-03 JP JP2019556742A patent/JP7217710B2/ja active Active
- 2018-01-03 US US16/475,299 patent/US10995137B2/en active Active
- 2018-01-03 CN CN201880005729.4A patent/CN110267985B/zh active Active
- 2018-01-03 BR BR112018067721A patent/BR112018067721A2/pt unknown
- 2018-01-03 MA MA047205A patent/MA47205A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MA47205A (fr) | 2019-11-13 |
EP3565836A1 (en) | 2019-11-13 |
US10995137B2 (en) | 2021-05-04 |
WO2018127519A1 (en) | 2018-07-12 |
CN110267985A (zh) | 2019-09-20 |
CN110267985B (zh) | 2023-05-23 |
JP7217710B2 (ja) | 2023-02-03 |
US20190330320A1 (en) | 2019-10-31 |
JP2020506954A (ja) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018067721A2 (pt) | anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares | |
CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
BR112016019432A8 (pt) | composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina | |
CO2017013356A2 (es) | Anticuerpos de factor xi | |
ECSP19029758A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
UY36194A (es) | Anticuerpos anti-tau humanizados | |
BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
UY33575A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
MX2020010968A (es) | Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades. | |
BR112018001275A2 (pt) | métodos para tratar transtornos associados à angiogênese e neovascularização | |
BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
BR112016017817A2 (pt) | composições e métodos para o tratamento e a prevenção de degeneração macular | |
BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
BR112021013096A2 (pt) | Tratamento de doença de sjögren com proteínas de fusão de nuclease | |
CR20170346A (es) | Composiciones para el tratamiento de infecciones producidas por el ácaro demodex spp | |
BR112017007095A2 (pt) | conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |